We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 01, 2021

Limited Primary Tumour Responses in Patients Treated With Nivolumab for mRCC

European Urology


Additional Info

European Urology
Primary Renal Tumour Response in Patients Treated With Nivolumab for Metastatic Renal Cell Carcinoma: Results From the GETUG-AFU 26 NIVOREN Trial
Eur Urol 2021 Jun 05;[EPub Ahead of Print], J Courcier, C Dalban, B Laguerre, S Ladoire, P Barthélémy, S Oudard, F Joly, G Gravis, C Chevreau, L Geoffrois, É Deluche, F Rolland, D Topart, S Culine, S Négrier, H Mahammedi, F Tantot, A Jamet, B Escudier, R Flippot, L Albigès

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading